Compound profile

TB-500

Healing peptide

A synthetic peptide fragment marketed as related to thymosin beta-4 (Tβ4), a tissue-repair protein, and used in community recovery protocols despite little human evidence.

Reviewed for accuracy · Last reviewed July 7, 2026
ClassThymosin beta-4 (Tβ4) fragment
RouteSubcutaneous injection
Common research range~2 – 2.5 mg, 1–2x weekly (community-cited)
StorageRefrigerated, ~4 weeks once mixed

Overview

TB-500 is a synthetic peptide sold as a recovery compound and marketed as related to thymosin beta-4 (Tβ4), a naturally occurring actin-binding protein involved in cell migration, angiogenesis, and tissue repair. A key honesty point: TB-500 is a fragment and is not structurally identical to full-length Tβ4, so evidence about Tβ4 does not automatically transfer to it.

The tissue-repair research that gets cited (wound healing, and cardiac repair after injury) was done on Tβ4 in animal models, not on TB-500 in humans. There are no controlled human trials of TB-500 for its marketed uses, it is not FDA-approved, and it is prohibited in drug-tested sport. Treat it as a research compound with a thin, indirect evidence base.

Dosing

There is no established human dose. Community protocols cite roughly 2 – 2.5 mg once or twice weekly by injection, often stacked with BPC-157. TB-500 is not FDA-approved and is prohibited in drug-tested sport.

Read the full TB-500 dosage guide →

Side effects

There are no controlled human trials, so its safety profile is not characterized. Reported effects are mostly local or vague (injection-site irritation, occasional fatigue), and the honest caveat is that the human evidence is essentially absent.

Read the full TB-500 side effects guide →

Storage

Keep unmixed vials refrigerated and away from light. Once reconstituted, most research reports store it refrigerated for roughly 4 weeks. See the full storage & safety guide for handling and disposal basics.

FAQ

Is TB-500 the same as thymosin beta-4?Not exactly. TB-500 is a synthetic fragment marketed as related to thymosin beta-4, but it is not structurally identical to the full-length protein, so the animal research on Tβ4 does not automatically apply to it.
Is there human evidence for TB-500?There are no controlled human clinical trials of TB-500 for its marketed recovery uses. The tissue-repair evidence comes from animal studies of thymosin beta-4, and TB-500 is not FDA-approved.
Can TB-500 be stacked with BPC-157?They are frequently paired in community recovery protocols, but no clinical evidence establishes that the combination is safe or effective in humans. See the BPC-157 and TB-500 blend calculator for the dosing arithmetic, not an endorsement.

References

  1. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissuesTrends in Molecular Medicine · 2005 · PMID 16099219 · DOI 10.1016/j.molmed.2005.07.004
  2. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptideAnnals of the New York Academy of Sciences · 2010 · PMID 20536453 · DOI 10.1111/j.1749-6632.2010.05479.x
  3. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repairNature · 2004 · PMID 15565145 · DOI 10.1038/nature03000
Running this protocol? PepHub can log your doses and remind you.Learn more →

This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.